New drug may unmask hidden leukemia cells after treatment

NCT ID NCT07392970

First seen Feb 06, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study tests whether a single injection of motixafortide can help find leftover leukemia cells (called measurable residual disease, or MRD) in the blood of people with acute myeloid leukemia (AML) who have finished their first round of chemotherapy. Ten adults who are in remission will receive the drug and have their blood tested before and after to see if more hidden cancer cells become detectable. The goal is to improve how doctors measure remaining disease, not to treat the leukemia itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.